I hear a lot of excitement from NP and this board but I do not see how NP's video answers the most important question of near term financing. "Revenue" in Q2 2020 ( he never mentioned the word significant) and a NON-BINDING agreement sounds like additional dilutive financing is likely to be required.

The only revenue I've seen mentioned until now was selling tiny quantities of non-clinical grade leronlimab.

Hope I'm wrong. GLTA.